Glialign, a UK-based developer of a treatment for peripheral nerve damage spun out from University College London (UCL), has raised an undisclosed sum from backers including the institution’s UCL Technology Fund.
The government-backed UK Innovation & Science Seed Fund (UKI2S), a patient capital fund targeting British spinouts, and public body Innovate UK also took part in the funding round.
Founded in 2016, Glialign is working on a cell therapy for peripheral nerve repair. The technology, Engineered Neural Tissue (EngNT), offers an…
